{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:07:45Z","timestamp":1768284465921,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10792-011-9495-z","type":"journal-article","created":{"date-parts":[[2011,12,29]],"date-time":"2011-12-29T06:25:27Z","timestamp":1325139927000},"page":"447-451","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of fixed combinations of dorzolamide\/timolol and brimonidine\/timolol in patients with primary open-angle glaucoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Gokhan","family":"Gulkilik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersin","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"Odabas\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,30]]},"reference":[{"key":"9495_CR1","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ et al (2002) The ocular hypertension treatment study: a randomized trial determines that topical medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701\u2013713","journal-title":"Arch Ophthalmol"},{"key":"9495_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group (CNTG)","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group (CNTG) (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487\u2013497","journal-title":"Am J Ophthalmol"},{"key":"9495_CR3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","volume":"130","author":"AGIS Investigators","year":"2000","unstructured":"AGIS Investigators (2000) The Advanced Glaucoma Intervention Study (AGIS), 7: the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429\u2013440","journal-title":"Am J Ophthalmol"},{"key":"9495_CR4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0161-6420(01)00873-9","volume":"108","author":"PR Lichter","year":"2001","unstructured":"Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, Mills RP, CIGTS Study Group (2001) Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. Ophthalmology 108:1943\u20131953","journal-title":"Ophthalmology"},{"key":"9495_CR5","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","volume":"124","author":"MB Sherwood","year":"2006","unstructured":"Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM (2006) Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 124:1230\u20131238","journal-title":"Arch Ophthalmol"},{"key":"9495_CR6","first-page":"1","volume":"4","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ (2010) Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 4:1\u20139","journal-title":"Clin Ophthalmol"},{"key":"9495_CR7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JS, van de Borne BW, Webers CA (2005) Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 112:953\u2013961","journal-title":"Ophthalmology"},{"key":"9495_CR8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ophtha.2005.10.034","volume":"113","author":"B Sleath","year":"2006","unstructured":"Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad B (2006) Patient reported behavior and problems in using glaucoma medications. Ophthalmology 113:431\u2013436","journal-title":"Ophthalmology"},{"key":"9495_CR9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1185\/03007990902994041","volume":"25","author":"DR Nixon","year":"2009","unstructured":"Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA (2009) Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin 25:1645\u20131653","journal-title":"Curr Med Res Opin"},{"key":"9495_CR10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s004170050356","volume":"238","author":"M Centofanti","year":"2000","unstructured":"Centofanti M, Manni G, Gregori D et al (2000) Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Graefes Arch Clin Exp Ophthalmol 238:302\u2013305","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"9495_CR11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1185\/03007995.2010.482017","volume":"26","author":"J Garc\u00eda-Feijo\u00f3","year":"2010","unstructured":"Garc\u00eda-Feijo\u00f3 J, S\u00e1enz-Franc\u00e9s F, Mart\u00ednez-de-la-Casa JM et al (2010) Comparison of ocular hypotensive actions of fixed combinations of brimonidine\/timolol and dorzolamide\/timolol. Curr Med Res Opin 26:1599\u20131606","journal-title":"Curr Med Res Opin"},{"key":"9495_CR12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1185\/030079907X178694","volume":"23","author":"ES Arcieri","year":"2007","unstructured":"Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, S\u00e1 Filho WF (2007) Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin 23:683\u2013689","journal-title":"Curr Med Res Opin"},{"key":"9495_CR13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/jop.2006.0131","volume":"23","author":"K Chan","year":"2007","unstructured":"Chan K, Testa M, McCluskey P (2007) Ocular comfort of combination glaucoma therapies: brimonidine 0.2%\/timolol 0.5% compared with dorzolamide 2%\/timolol 0.5%. J Ocul Pharmacol Ther 23:372\u2013376","journal-title":"J Ocul Pharmacol Ther"},{"key":"9495_CR14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0161-6420(02)01900-0","volume":"110","author":"KN Sall","year":"2003","unstructured":"Sall KN, Greff LJ, Johnson-Pratt LR et al (2003) Dorzolamide\/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 110:615\u2013624","journal-title":"Ophthalmology"},{"key":"9495_CR15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bjo.2003.032979","volume":"88","author":"ED Sharpe","year":"2004","unstructured":"Sharpe ED, Day DG, Beischel CJ, Rhodes JS, Stewart JA, Stewart WC (2004) Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 88:953\u2013956","journal-title":"Br J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-011-9495-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-011-9495-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-011-9495-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T20:30:24Z","timestamp":1559248224000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-011-9495-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9495"],"URL":"https:\/\/doi.org\/10.1007\/s10792-011-9495-z","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}